KR102200628B1 - Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체 - Google Patents
Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체 Download PDFInfo
- Publication number
- KR102200628B1 KR102200628B1 KR1020157010728A KR20157010728A KR102200628B1 KR 102200628 B1 KR102200628 B1 KR 102200628B1 KR 1020157010728 A KR1020157010728 A KR 1020157010728A KR 20157010728 A KR20157010728 A KR 20157010728A KR 102200628 B1 KR102200628 B1 KR 102200628B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compounds
- compound
- pharmaceutically acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 | ||
| EP12006707.9 | 2012-09-26 | ||
| PCT/EP2013/002577 WO2014048532A1 (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150063474A KR20150063474A (ko) | 2015-06-09 |
| KR102200628B1 true KR102200628B1 (ko) | 2021-01-08 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157010728A Expired - Fee Related KR102200628B1 (ko) | 2012-09-26 | 2013-08-27 | Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (enExample) |
| EP (1) | EP2900643B1 (enExample) |
| JP (1) | JP6276769B2 (enExample) |
| KR (1) | KR102200628B1 (enExample) |
| CN (1) | CN104662006B (enExample) |
| AR (1) | AR092670A1 (enExample) |
| AU (1) | AU2013324681B2 (enExample) |
| BR (1) | BR112015006524A8 (enExample) |
| CA (1) | CA2886000C (enExample) |
| ES (1) | ES2654464T3 (enExample) |
| IL (1) | IL237840A (enExample) |
| MX (1) | MX362855B (enExample) |
| RU (1) | RU2650107C2 (enExample) |
| SG (1) | SG11201502120XA (enExample) |
| WO (1) | WO2014048532A1 (enExample) |
| ZA (1) | ZA201502838B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800662T1 (it) | 2011-12-22 | 2019-01-11 | Alios Biopharma Inc | Nucleotidi, nucleosidi sostituiti e loro analoghi |
| DK2822656T3 (en) | 2012-03-07 | 2017-01-30 | Inst Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PL2861611T3 (pl) | 2012-05-25 | 2017-08-31 | Janssen Sciences Ireland Uc | Nukleozydy uracylowe spirooksetanu |
| EP3912984A1 (en) | 2012-12-21 | 2021-11-24 | Janssen BioPharma, Inc. | 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv |
| WO2015036759A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US10626094B2 (en) | 2014-10-14 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| WO2018204176A1 (en) * | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
| WO2019131798A1 (ja) * | 2017-12-27 | 2019-07-04 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| WO2019131794A1 (ja) * | 2017-12-27 | 2019-07-04 | 公益財団法人がん研究会 | 抗がん剤 |
| EP4021895A1 (en) * | 2019-08-28 | 2022-07-06 | F. Hoffmann-La Roche AG | Novel quinazoline compounds for the treatment and prophylaxis of hepatitis b virus disease |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025221809A1 (en) * | 2024-04-16 | 2025-10-23 | Eluciderm Inc. | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014873A1 (ja) | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| WO2012028578A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Cropscience Ag | Substituierte anellierte pyrimidinone und dihydropyrimidinone |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1020445B1 (en) | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| WO2006098969A2 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| CA2678248C (en) | 2007-03-08 | 2016-06-28 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
| MX392179B (es) * | 2009-03-18 | 2025-03-21 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2013
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en not_active Ceased
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko not_active Expired - Fee Related
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014873A1 (ja) | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| WO2012028578A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Cropscience Ag | Substituierte anellierte pyrimidinone und dihydropyrimidinone |
Non-Patent Citations (1)
| Title |
|---|
| Costantino 외, J. Med. Chem., Vol. 44, No. 23 pp 3786-3794, 2001* |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2654464T3 (es) | 2018-02-13 |
| SG11201502120XA (en) | 2015-04-29 |
| MX362855B (es) | 2019-02-20 |
| KR20150063474A (ko) | 2015-06-09 |
| AU2013324681A1 (en) | 2015-05-07 |
| WO2014048532A1 (en) | 2014-04-03 |
| EP2900643B1 (en) | 2017-09-27 |
| CA2886000A1 (en) | 2014-04-03 |
| MX2015003570A (es) | 2015-06-22 |
| EP2900643A1 (en) | 2015-08-05 |
| CA2886000C (en) | 2020-11-10 |
| AU2013324681B2 (en) | 2017-08-10 |
| JP2015535831A (ja) | 2015-12-17 |
| CN104662006B (zh) | 2017-10-24 |
| RU2650107C2 (ru) | 2018-04-09 |
| CN104662006A (zh) | 2015-05-27 |
| BR112015006524A8 (pt) | 2019-08-20 |
| HK1210777A1 (en) | 2016-05-06 |
| ZA201502838B (en) | 2017-11-29 |
| RU2015115576A (ru) | 2016-11-20 |
| JP6276769B2 (ja) | 2018-02-07 |
| BR112015006524A2 (pt) | 2017-07-04 |
| AR092670A1 (es) | 2015-04-29 |
| IL237840A (en) | 2017-05-29 |
| US9388142B2 (en) | 2016-07-12 |
| US20150239850A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102200628B1 (ko) | Ｐａｒｐ 억제제로서의 퀴나졸리논 유도체 | |
| KR102083154B1 (ko) | （아자―）이소퀴놀리논 유도체 | |
| KR102070567B1 (ko) | 바이시클릭 피라지논 유도체 | |
| JP6097820B2 (ja) | ピロロトリアジノン誘導体 | |
| TWI572593B (zh) | 四氫喹唑啉酮衍生物 | |
| HK1210777B (en) | Quinazolinone derivatives as parp inhibitors | |
| HK1209106B (en) | (aza-)isoquinolinone derivatives | |
| HK1205740B (en) | Pyrrolotriazinone derivatives | |
| HK1202551B (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| HK1203961B (en) | Bicyclic pyrazinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20240106 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20240106 |